---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257388"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-06-04T20:06:56+00:00"
generated_at: "2026-06-04T20:29:24.606771+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Kalaris Therapeutics holds 2026 annual meeting; all proposals pass

## Summary
- Elected Napoleone Ferrara, David Hallal, Leone Patterson as Class III directors (three-year terms).
- Advisory vote on executive compensation approved: 15.85M for, 0.50M against.
- Shareholders recommended say-on-pay every year; board adopts annual frequency.
- Ratified Deloitte & Touche as auditor for FY 2026: 19.77M for, 1.58K against.

## SEC filing metadata
- accession: 0001193125-26-257388
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-06-04T20:06:56+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/d85626d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257388
- JSON: https://secwatch.observer/filing/0001193125-26-257388.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257388.txt

## Key facts
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-03 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The stockholders of the Company recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors Napoleone Ferrara, M.D., David Hallal and Leone Patterson at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The stockholders of the Company elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-03 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.